Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
View original at finance.yahoo.com“Revenue: Total revenue for the fourth quarter of 2025 was $678 million, on the higher end of the Company's prior expectations”
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
2026 SG&A expenses projected to be approximately $1.0 billion
80% confidenceModerna expects potential propionic acidemia therapeutic data readout in 2026
80% confidenceModerna is poised to deliver up to 10 percent revenue growth through mNEXSPIKE expansion and international strategic partnerships
80% confidenceIntismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% compared to KEYTRUDA alone in five-year Phase 2b adjuvant melanoma data
80% confidence2026 revenue targeting up to 10% growth from 2025 with approximately 50% U.S. and 50% international split
80% confidenceModerna expects potential Phase 2 mRNA-4359 data readout in 2026
80% confidenceIn 2025, Moderna sharpened commercial execution, launched third product and brought online three international manufacturing sites, while advancing mRNA pipeline and lowering annual operating expenses by approximately $2.2 billion
80% confidenceSeasonal vaccines expected to deliver up to 10% revenue growth in 2026
80% confidenceModerna expects potential Phase 3 adjuvant melanoma data in 2026
80% confidence2026 cost of sales expected to be approximately $0.9 billion
80% confidenceModerna looks forward to delivering multiple potential product approvals and late-stage clinical readouts, while driving continued innovation across mRNA platform
80% confidenceYear-end 2026 cash and investments projected to be $5.5 to $6.0 billion, excluding any additional credit facility drawdown
80% confidence2026 R&D expenses anticipated to be approximately $3.0 billion
80% confidence